公开(公告)号：US20230365582A1

公开(公告)日：2023-11-16

申请号：US18042352

申请日：2021-08-20

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Young Sook SHIN ,  Sang Kyun LIM ,  Yeri LEE ,  Donggeon KIM ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyun Jin KIM ,  Joo Youn LEE ,  Hyuk LEE ,  Sikwang SEONG

IPC: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

CPC classification number: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.

公开(公告)号：US20240400518A1

公开(公告)日：2024-12-05

申请号：US18684629

申请日：2022-08-17

Applicant: KANAPH THERAPEUTICS INC. ,  CYRUS THERAPEUTICS INC.

Inventor： Ha Na YU ,  Young Sook SHIN ,  Dohyun PARK ,  Kyeong Jin YOON ,  Sang Kyun LIM ,  Donggeon KIM ,  Dong Hyuk KI ,  Eun-Jung KIM ,  Joonwoo NAM ,  Wooseok HAN ,  Jihyun YU ,  Ji Eun KIM

IPC: C07D231/22 ,  A61K31/4418 ,  A61K31/4965 ,  A61K31/501 ,  C07D213/87 ,  C07D241/24

Abstract: There is provided a novel compound of Formula I and a use thereof for the prevention or treatment of a disease associated with SOS1. In one aspect of the present invention, the novel compound is useful for the prevention or treatment of a SOS1 mediated disease such as cancer and RASopathy by inhibiting the interaction between SOS1 and RAS family proteins or between SOS1 and RAC1.

公开(公告)号：US20250161271A1

公开(公告)日：2025-05-22

申请号：US18838591

申请日：2023-02-15

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Donggeon KIM ,  Yeri LEE ,  Sang Kyun LIM ,  Young Sook SHIN ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyuk LEE ,  Hyun Jin KIM ,  Joo Youn LEE ,  Si Kwang SEONG ,  Taeyoung YOON ,  Youngrae LEE

IPC: A61K31/407 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4155 ,  A61K31/4436 ,  A61K31/4535 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.

公开(公告)号：US20240189306A1

公开(公告)日：2024-06-13

申请号：US18407400

申请日：2024-01-08

Applicant: KANAPH THERAPEUTICS INC.

Inventor： Miyeon KIM ,  Dohyun PARK ,  Dongsu KIM ,  Kyeongjin YOON ,  Sungpil CHOI ,  Sang Kyun LIM ,  Eu Ddeum CHUNG ,  Mijung LEE ,  Dahye JEON ,  Soyeon JANG ,  Kyungik LEE ,  Jinhwan KIM ,  Eunji KIM ,  Jieun MIN ,  Kangwoo LEE ,  Jakyung YOO

IPC: A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K31/53 ,  A61K31/551 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D519/00

CPC classification number: A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K31/53 ,  A61K31/551 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D519/00

Abstract: The present invention relates to an inhibitor of SHP2, a pharmaceutical composition for preventing or treating a disease related to SHP2 comprising the same, a method for treating and preventing a disease using the same, and a use thereof. Accordingly, the present invention can effectively prevent or treat diseases related to SHP2.